Keysight Technologies Inc vs NeoGenomics Inc. Common Stock — how do they compare? Keysight Technologies Inc trades at $352.53 (market cap $63.03B), while NeoGenomics Inc. Common Stock trades at $16.85 (market cap $2.14B). The key difference: Keysight Technologies Inc is far larger — about 29.5× NeoGenomics Inc. Common Stock's market cap, and NeoGenomics Inc. Common Stock is more actively traded (2,228,400 versus 1,168,526). Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 57 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| KEYS | NEO | |
|---|---|---|
Market Cap | $63.03B | $2.14B |
Volume | 1,168,526 | 2,228,400 |
Sector | Technology | Health |
52-Week High | $387.90 | $19.91 |
52-Week Low | $162.19 | $7.19 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $63.17B | $2.44B |
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $357.59, down 5.32% over 24 hours, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.07 exceeding expectations. Revenue for 2025 reached $5.38 billion, with a net income margin of 15.81%. Recent news highlights growth in AI infrastructure and 6G testing solutions.
The outlook remains positive with a consensus price target of $421.29, implying significant upside. Risks include elevated valuation multiples and supply constraints affecting near-term revenue conversion. Institutional sentiment is bullish, with 81% of analysts rating the stock a buy.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →